Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Assets (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Assets for 12 consecutive years, with $472.7 million as the latest value for Q1 2026.

  • For Q1 2026, Assets fell 26.23% year-over-year to $472.7 million; the TTM value through Mar 2026 reached $472.7 million, down 26.23%, while the annual FY2025 figure was $529.7 million, 26.92% down from the prior year.
  • Assets hit $472.7 million in Q1 2026 for Syndax Pharmaceuticals, down from $529.7 million in the prior quarter.
  • Across five years, Assets topped out at $724.8 million in Q4 2024 and bottomed at $359.7 million in Q3 2022.
  • Average Assets over 5 years is $503.0 million, with a median of $476.9 million recorded in 2024.
  • Year-over-year, Assets surged 54.5% in 2022 and then fell 26.92% in 2025.
  • Syndax Pharmaceuticals' Assets stood at $497.2 million in 2022, then grew by 23.26% to $612.9 million in 2023, then increased by 18.26% to $724.8 million in 2024, then dropped by 26.92% to $529.7 million in 2025, then fell by 10.77% to $472.7 million in 2026.
  • According to Business Quant data, Assets over the past three periods came in at $472.7 million, $529.7 million, and $551.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.